Can-Fite BioPharma ADR shares advanced in pre-open trading, rising 2.3% following the company announcement that it has completed patient enrollment for the interim analysis of its pivotal Phase 3 study in psoriasis. The company said interim data from the trial are expected to be disclosed in Q4 2026 or Q1 2027.
The notice of enrollment completion was filed with the U.S. Securities and Exchange Commission as a Form 6-K on July 6, 2026. The achievement represents a procedural milestone for Can-Fite's leading inflammatory disease program, which centers on its oral candidate Piclidenoson.
This update adds to a string of favorable developments that have recently influenced the stock. Earlier in the week, Can-Fite reported Phase 2a findings for Namodenoson, its oncology candidate for advanced pancreatic cancer. That study met its primary safety endpoint and indicated durable survival outcomes in a patient population described as difficult to treat.
Analyst coverage has remained supportive through the latest newsflow. HC Wainwright has kept a Buy rating on the shares and assigns a price target of $8.00, a factor market participants have pointed to when assessing the equity's outlook.
Market-wide action on the day was mixed. The Dow Jones rose by 1.1% while the Nasdaq slipped 0.8%, a divergence that underscored uneven sector performance. Those broader moves did not appear to be the dominant influence on Can-Fite's trading, as the company's own announcements have driven activity in the stock.
Intra-session trading reflected the name's typical volatility for a micro-cap clinical-stage biotech. The equity recorded a session high of $4.60 and a low of $3.50, with pre-market pricing around $4.00. Such price swings are consistent with a catalyst-driven profile where discrete trial milestones and clinical updates often produce sizable short-term moves.
Taken together, the completion of Phase 3 enrollment for Piclidenoson gives the market a specific near-term data event to price. At the same time, carryover momentum from the Namodenoson pancreatic cancer update and continued analyst endorsement from HC Wainwright have helped keep buyer interest alive in pre-market trading.
Summary
- Can-Fite reported completion of patient enrollment for the interim analysis of its pivotal Phase 3 psoriasis study; interim data expected Q4 2026 or Q1 2027.
- Company filed the announcement as a Form 6-K on July 6, 2026.
- Recent Phase 2a Namodenoson results in advanced pancreatic cancer met the primary safety endpoint and showed durable survival outcomes.
- HC Wainwright maintains a Buy rating with an $8.00 price target.
- Stock displayed wide trading ranges, reflecting a high-volatility, catalyst-driven micro-cap profile.